Clinical Trial Update: Efficacy and Safety of Alirocumab Versus Usual Care on Top of Maximally Tolerated Statin Therapy in Patients With Type 2 Diabetes and Mixed Dyslipidemia (ODYSSEY DM-Dyslipidemia) [Phase 4]

View source ↗

Summary

Phase 4 ODYSSEY DM-Dyslipidemia trial comparing alirocumab added to maximally tolerated statin therapy versus usual care in patients with type 2 diabetes and mi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dyslipidemia
• Type 2 Diabetes Mellitus

Drugs mentioned

• Alirocumab (Praluent) (alirocumab)

Snippet

Sponsor: Sanofi | Conditions: Dyslipidemia | Phase 4 | Status: COMPLETED | Results posted: 2018-05-01